The first payments could reach $100 million for Rona Therapeutics’ investigational obesity drug candidate. Up to $1.06 billion more is tied to development and regulatory milestones, with commercial milestones also included. Rona is eligible for tiered royalties on global net sales, according to a Reuters deal report.
Rona announced the exclusive global license on October 13, 2026. Roche gains another experimental asset as it seeks a foothold in an obesity drug market dominated by Eli Lilly and Novo Nordisk. The candidate uses RNA interference and Rona’s delivery platform for extra-vascular tissues, according to the official Rona announcement.
ALK7 is encoded by the ACVR1C gene and is predominantly expressed in adipose tissue. Rona says suppressing it could potentially reduce visceral and other ectopic fat while preserving lean mass, but these are proposed benefits, not published clinical results.
An RNAi candidate aimed at ALK7
Rona’s candidate targets activin receptor-like kinase 7, or ALK7, which the companies identify as a target for obesity and metabolic diseases. The announcement does not say how far the candidate has progressed in clinical development. It reports no trial results or safety findings, and gives no timetable. The deal’s headline value is no evidence of effectiveness.
The deal’s clinical evidence remains undisclosed, despite its headline value of up to $1.16 billion.
Rona describes ALK7 inhibition as a direct approach to adipocytes, distinct from incretin-based medicines. The company has presented it as a potential component of combination therapy with incretins.
Roche is building more than one obesity bet
In September 2026, Roche reported positive interim data for enicepatide, its obesity and diabetes candidate. The company said patients lost weight and lowered blood sugar levels. Those findings concern enicepatide, not Rona’s ALK7-targeting RNAi programme.
The licensing route from a Chinese biotech to a major drugmaker also recalls Novo Nordisk’s UBT251 deal, another obesity-drug transaction involving a candidate developed in China.
Roche’s agreement announcement does not disclose the candidate’s clinical development stage.
